ELMWOOD PARK, N.J., July 21, 2020 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company, today announced that Geoff Monk, President of BioReference Laboratories, was recognized by CEO Today Magazine as one of this year’s 20 Healthcare Award winners.
Every year, CEO Today Magazine identifies and honors the most respected companies and their executives who lead the way on the global stage. CEO Today Magazine’s Healthcare Awards acknowledge trailblazing leaders and the vital contributions made by those working to solve common healthcare issues that face society today.
“Considering CEO Today Magazine recognizes the essential role that healthcare companies play in providing solutions for healthcare needs as well as continually pushing scientific boundaries, it is an honor to join fellow winners of CEO Today Healthcare Awards,” said Monk. “I am proud of BioReference’s advances in diagnostics, which were amplified during the COVID-19 pandemic, as we’ve expanded testing capacity and added multiple platforms and testing; 2020 has proved to be a year of innovation, discovery and evolving necessities in the healthcare industry, so to be acknowledged by CEO Today Magazine this year is a privilege.”
“Geoff is a natural addition to join his fellow winners of the 2020 CEO Today’s Healthcare Awards,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “2020 has also given Geoff the opportunity to lead BioReference and advance the operational and business strategies within the company based on the current healthcare landscape. So for him to be awarded CEO Today’s Healthcare Awards, truly showcases his dedication to the industry and his peers.”
Geoff joined BioReference Laboratories in 2018 as General Manager and was promoted to President in early 2019 in recognition of the significant progress made in achieving greater operational efficiency to position BioReference for profitable growth. Previously, Geoff served as Vice President of Operations for the East Region at Quest Diagnostics, following a spell as Managing Director for their New York/New Jersey region where he had full P&L responsibility. Geoff’s guiding principles are to follow the path of continuous improvement to operational excellence and that there is an optimal solution for every problem. He received his M.A. in Engineering from the University of Cambridge, UK and became a Chartered Engineer through the Institute of Mechanical Engineers.
The 2020 CEO Today Healthcare Awards is featured in the latest issue of CEO Today Magazine, and includes profiles of the nominees available at https://healthcareawards.ceotodaymagazine.com/.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding BioReference’s antibody screening test, the availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of employees and customers, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
SOURCE BioReference Laboratories, Inc.
